Rybelsus for weight loss: what the before-and-afters don't show
Quick answer
The creator used oral semaglutide (Rybelsus) for approximately 12 months, achieving a 44-pound weight reduction from a starting weight of 192 pounds, and has been off the medication for nearly a year. She reports modest weight regain of approximately 9 pounds coinciding with the return of food cravings, which is consistent with the known pharmacodynamics of GLP-1 receptor agonist withdrawal and supported by post-trial follow-up data. She identifies as prediabetic, which may have been the clinical indication for the Rybelsus prescription, as the drug carries FDA approval for type 2 diabetes management rather than primary weight loss.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Rybelsus for weight loss: what the before-and-afters don't show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Rybelsus for weight loss: what the before-and-afters don't show is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Rybelsus for weight loss: what the before-and-afters don't show" from Adriana. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator used oral semaglutide (Rybelsus) for approximately 12 months, achieving a 44-pound weight reduction from a starting weight of 192 pounds, and has been off the medication for nearly a year.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to d before and after rybelsus this is so hard for." In this clip, the useful excerpt is: "I lost 44 pounds on my Bellsias in a whole year and I am replying to this comment I do have some before and after pictures which I will show you guys right now if You're interested in seeing but I was on it for a whole year." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator used oral semaglutide (Rybelsus) for approximately 12 months, achieving a 44-pound weight reduction from a starting weight of 192 pounds, and has been off the medication for nearly a year.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator used oral semaglutide (Rybelsus) for approximately 12 months, achieving a 44-pound weight reduction from a starting weight of 192 pounds, and has been off the medication for nearly a year. She reports modest weight regain of approximately 9 pounds coinciding with the return of food cravings, which is consistent with the known pharmacodynamics of GLP-1 receptor agonist withdrawal and supported by post-trial follow-up data. She identifies as prediabetic, which may have been the clinical indication for the Rybelsus prescription, as the drug carries FDA approval for type 2 diabetes management rather than primary weight loss.
- Rybelsus is FDA-approved for type 2 diabetes, not weight loss. Wegovy (semaglutide 2.4 mg injectable) holds the FDA weight-loss indication. Off-label prescribing for weight management does occur but patients should know the distinction.
- Weight regain after stopping semaglutide is the rule, not the exception. STEP 1 follow-up data (Wilding et al., 2022, NEJM) found participants regained about two-thirds of lost weight within one year of stopping the medication.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Rybelsus is FDA-approved for type 2 diabetes, not weight loss. Wegovy (semaglutide 2.4 mg injectable) holds the FDA weight-loss indication. Off-label prescribing for weight management does occur but patients should know the distinction.
- Weight regain after stopping semaglutide is the rule, not the exception. STEP 1 follow-up data (Wilding et al., 2022, NEJM) found participants regained about two-thirds of lost weight within one year of stopping the medication.
- Oral semaglutide has roughly 1% bioavailability compared to injectable forms, which is why clinical trials show modestly lower average weight loss for Rybelsus than Wegovy. A 23% body weight reduction in one year is above the average seen in the OASIS 1 trial.
- Returning food cravings after stopping a GLP-1 medication are not a willpower failure. They reflect the reversal of drug-mediated suppression of appetite-signaling pathways in the hypothalamus. Rubino et al. (2021, NEJM) confirmed appetite hormones rebound within weeks of discontinuation.
- Obesity and weight regain should be treated as chronic condition management, not a single intervention. Stopping medication without a maintenance plan, whether behavioral, dietary, or pharmacological, is associated with nearly complete return to baseline weight over time.
- The creator's plan to consult her doctor if self-managed efforts fail is the correct approach. Resuming medication, switching formulations, or adding structured behavioral support are all clinically valid options that should be assessed by a licensed provider with full patient history.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @la_adriana01 actually say?
She lost 44 pounds over one year on Rybelsus (oral semaglutide), dropping from 192 to 148 pounds. After stopping, she held steady around 150 for several months before creeping back to 157. She's now off the medication for nearly a year, dealing with returning food cravings, and considering whether to go back to her doctor.
This is a personal weight-loss story, not a medical claim. She's not telling you to take Rybelsus, not dosing you, not selling anything. She's showing before-and-after photos and admitting she's struggling. That framing matters for how we read this: most of what she describes is consistent with how semaglutide actually works, and she's more honest about the limitations than most GLP-1 content on TikTok.
Does the science back this up?
Yes, mostly. A 44-pound loss over 12 months on oral semaglutide is on the higher end but biologically plausible. Weight regain after stopping is not just expected, it's nearly guaranteed, and the science on this is blunt.
The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) tracked participants for 68 weeks after stopping injectable semaglutide 2.4 mg. Within one year, they regained two-thirds of their lost weight. Oral semaglutide delivers lower and more variable bioavailability than injectable forms, roughly 1% absorption, so weight loss outcomes are generally more modest. The OASIS 1 trial (Davies et al., 2023, The Lancet) showed oral semaglutide 50 mg produced about 15% body weight reduction over 68 weeks in non-diabetic adults. Her 23% loss over 12 months at presumably lower doses is notable but not impossible depending on starting metabolic conditions.
The return of food cravings she describes, what she calls "the munchies," is mechanistically explained. GLP-1 receptor agonists reduce appetite partly through central nervous system signaling in the hypothalamus. When the drug clears, those hunger-suppressing signals go with it.
What did they get wrong (or right)?
She got the core narrative right. Weight comes back when you stop. Cravings return. The drug is not a permanent fix. That's accurate and worth saying clearly because a lot of GLP-1 content skips that part entirely.
Two things are worth flagging. First, she frames regaining 9 pounds over nearly a year as "sucking" and says she's "embarrassed." That framing is understandable but medically misleading by omission. Gaining back a small fraction of lost weight after stopping a powerful appetite-suppressing drug is not a personal failure. It is a predictable pharmacological outcome. The STEP 1 follow-up data is unambiguous: the body's homeostatic mechanisms work against weight maintenance once the drug is gone.
Second, she mentions wanting a "facelift" or "neck lift" for loose skin after weight loss. That's a personal choice, not a medical concern we need to weigh in on. But she notes she's already spoken to a doctor, which is the right step.
She does not make any dangerous claims. She does not recommend dosages, suggest the drug cures diabetes, or compare compounded semaglutide to brand-name products. For TikTok GLP-1 content, that's a higher bar than most creators clear.
What should you actually know?
Rybelsus is FDA-approved for type 2 diabetes, not for weight loss. Wegovy (injectable semaglutide 2.4 mg) is the FDA-approved weight-loss formulation. Doctors can and do prescribe Rybelsus off-label for weight management, which is likely what happened here, but that distinction matters.
Weight regain after stopping GLP-1 medications is not a niche side effect. It is the default outcome. Rubino et al. (2021, NEJM) showed that stopping semaglutide after a treatment period resulted in return of hunger hormones and reversal of metabolic improvements within weeks. Obesity functions like a chronic condition requiring ongoing management, and stopping medication without a maintenance plan is likely to undo progress.
Her instinct, "if I start seeing no difference, I'm just gonna go back to the doctor," is actually the right approach. That conversation, deciding whether to resume, switch medications, or add behavioral support, should happen with a licensed provider who has access to her full history. She seems to understand this. That's worth acknowledging.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Adriana · TikTok creator
30.3K views on this video
Replying to @D🌹 Before and After Rybelsus. This is so hard for me to do! Still after loosing a lot of weight. I’m still struggling 😔🥺 #rybelsus #weightloss #glp1 #food #struggles #depression #prediabetic #lifeishard
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the evidence say about rybelsus?
Rybelsus is FDA-approved for type 2 diabetes, not weight loss. Wegovy (semaglutide 2.4 mg injectable) holds the FDA weight-loss indication. Off-label prescribing for weight management does occur but patients should know the distinction.
What does the evidence say about weight regain after stopping semaglutide?
Weight regain after stopping semaglutide is the rule, not the exception. STEP 1 follow-up data (Wilding et al., 2022, NEJM) found participants regained about two-thirds of lost weight within one year of stopping the medication.
What does the evidence say about oral semaglutide has roughly 1% bioavailability compared to injectable forms?
Oral semaglutide has roughly 1% bioavailability compared to injectable forms, which is why clinical trials show modestly lower average weight loss for Rybelsus than Wegovy. A 23% body weight reduction in one year is above the average seen in the OASIS 1 trial.
What does the evidence say about returning food cravings after stopping a glp-1 medication?
Returning food cravings after stopping a GLP-1 medication are not a willpower failure. They reflect the reversal of drug-mediated suppression of appetite-signaling pathways in the hypothalamus. Rubino et al. (2021, NEJM) confirmed appetite hormones rebound within weeks of discontinuation.
What does the evidence say about obesity?
Obesity and weight regain should be treated as chronic condition management, not a single intervention. Stopping medication without a maintenance plan, whether behavioral, dietary, or pharmacological, is associated with nearly complete return to baseline weight over time.
What does the evidence say about the creator's plan to consult her doctor if self-managed efforts?
The creator's plan to consult her doctor if self-managed efforts fail is the correct approach. Resuming medication, switching formulations, or adding structured behavioral support are all clinically valid options that should be assessed by a licensed provider with full patient history.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Adriana, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.